

# Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer

## Agenda

**SATURDAY – October 27, 2018**

7:00 AM Registration and Continental Breakfast

7:55 AM Welcome and Introductions.....*John Heymach, MD*

### EGFR-TKI TARGETED THERAPY

8:00 AM Pretest – Case Report Vignettes..... *John V. Heymach, MD, PhD / Don L. Gibbons, MD, PhD*

8:15 AM Molecular Profiling in the Treatment of NSCLC: .....*John V. Heymach, MD, PhD*  
Guidelines from the CAP, IASLC and AMP

8:45 AM EGFR Inhibitors: Perspective on Molecular Markers and .....*Don L. Gibbons, MD, PhD*  
Patient Selection

9:15 AM Emerging Strategies and Challenges Due to Secondary .....*Don L. Gibbons, MD, PhD*  
or Acquired EGFR-TKI Resistance

9:45 AM Posttest – Case Report Vignettes .....*John V. Heymach, MD, PhD / Don L. Gibbons, MD, PhD*

10:00 AM BREAK

### IMMUNOTHERAPY - NSCLC

10:15 AM Pretest – Case Report Vignettes.....*John V. Heymach, MD, PhD / Jianjun Zhang, MD, PhD*

10:30 AM Immunotherapy with PD-1/PD-L1 (Nivolumab, Pembrolizumab, .....*John V. Heymach, MD*  
Durvalumab) and Anti CTLA-4 (Ipilimumab) Antibodies in NSCLC

11:00 AM Immunotherapy with Anti-PD-L1 (Pembrolizumab) and .....*Jianjun Zhang, MD, PhD*  
Combination Therapy Approaches in NSCLC

11:30 AM Posttest – Case Report Vignettes .....*John V. Heymach, MD, PhD / Jianjun Zhang, MD, PhD*

### IMMUNOTHERAPY – HEAD & NECK CANCER

11:45 AM Pretest – Case Report Vignettes.....*Tanguy Seiwert, MD*

12:00 PM Overview of Molecular, Histologic Tumor Testing, High.....*Tanguy Seiwert, MD*  
Mutational Burden and Implication of Immune Resistance in  
HPV-associated Head & Neck Cancer

12:30 PM LUNCH

1:15 PM Immunotherapy Options in the Treatment of Metastatic .....*Tanguy Seiwert, MD*  
Head & Neck Cancer

1:45 PM Posttest – Case Report Vignettes .....*Tanguy Seiwert, MD*

### ALK-REARRANGED –TKI TARGETED THERAPY

2:00 PM Pretest – Case Report Vignettes.....*Anne Tsao, MD / Vincent Lam, MD*

2:15 PM Overview of Molecular Targeted Therapy on the Outcome of .....*Anne Tsao, MD*  
Early-stage NSCLC Patients with EML4-ALK Fusion Gene and the Application of TKIs

2:45 PM BREAK

3:00 PM Discuss Emerging Strategies and Challenges Due to Secondary .....*Vincent Lam, MD*  
or Acquired Resistance to Small Molecule TKIs in Patients with ALK-rearranged NSCLC

3:30 PM Posttest – Case Report Vignettes .....*Anne Tsao, MD / Vincent Lam, MD*

3:45 PM Adjournment.....*John V. Heymach, MD, PhD*